Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $4.1875.

A number of equities research analysts have recently commented on LUCD shares. Maxim Group cut their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Ascendiant Capital Markets upped their price objective on Lucid Diagnostics from $9.00 to $9.25 and gave the company a “buy” rating in a research report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a report on Friday, May 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research report on Thursday, March 26th.

Lucid Diagnostics Price Performance

Shares of Lucid Diagnostics stock opened at $1.05 on Thursday. Lucid Diagnostics has a 1 year low of $0.90 and a 1 year high of $1.63. The firm’s 50-day moving average is $1.04 and its 200 day moving average is $1.17. The stock has a market cap of $213.22 million, a price-to-earnings ratio of -2.23 and a beta of 1.07.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.38 million. On average, equities analysts expect that Lucid Diagnostics will post -0.23 EPS for the current fiscal year.

Insider Transactions at Lucid Diagnostics

In related news, Director Dennis Matheis bought 245,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $1.00 per share, for a total transaction of $245,000.00. Following the purchase, the director owned 1,033,443 shares of the company’s stock, valued at approximately $1,033,443. The trade was a 31.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Lucid Diagnostics

Large investors have recently made changes to their positions in the stock. Sprott Inc. bought a new position in Lucid Diagnostics during the third quarter valued at approximately $25,000. Centiva Capital LP bought a new stake in Lucid Diagnostics in the 3rd quarter worth approximately $25,000. Abel Hall LLC bought a new stake in Lucid Diagnostics in the 4th quarter worth approximately $33,000. JPMorgan Chase & Co. raised its stake in Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after buying an additional 32,672 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its stake in Lucid Diagnostics by 73.2% during the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company’s stock valued at $39,000 after buying an additional 14,487 shares during the last quarter. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.